<DOC>
	<DOCNO>NCT01965119</DOCNO>
	<brief_summary>The purpose study ruxolitinib may possible treatment option relapse refractory patient Hodgkin primary mediastinal large B-cell lymphoma .</brief_summary>
	<brief_title>Pilot Study Ruxolitinib Relapsed Refractory Hodgkin Lymphoma Primary Mediastinal Large B-cell Lymphoma</brief_title>
	<detailed_description>Patients take ruxolitinib 20 mg orally twice day , 40mg total per day , 4 weeks.4 week 1 cycle . Treatment continue documented disease progression unacceptable toxicity maximum period treatment 16 cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Histologically proven Hodgkin lymphoma primary mediastinal large Bcell lymphoma Patient belong one follow clinical situation A.Patient able get autologous stem cell transplantation relapse salvage chemotherapy B. Relapsed autologous stem cell transplantation C. Refractory salvage chemotherapy autologous stem cell transplantation Adequate organ function define follow criterion : A. Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase ( SGOT ) ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase ( SGPT ) ) ≤2.5 x local laboratory upper limit normal ( ULN ) , AST ALT less equal 5 x ULN liver function abnormality due underlying malignancy B . Total serum bilirubin ≤1.5 x ULN C. Absolute neutrophil count ( ANC ) ≥ 1500/µL D. Platelets ≥ 100,000/µL E. Hemoglobin ≥ 9.0 g/dL ( may transfuse erythropoietin treat ) F. Serum calcium ≤ 12.0 mg/dL G. Serum creatinine ≤ 1.5 x ULN At least one measurable lesion ECOG PS 02 Informed consent Age 19 80 Previously receive allogeneic stem cell transplantation History know carcinomatous meningitis , evidence symptomatic leptomeningeal disease secondary CNS involvement CT MRI scan . Currently uncontrolled active infection Previous history recurrent herpes zoster recurrent tuberculosis Ongoing cardiac dysrhythmias NCI CTCAE grade ≥2 . Pregnant lactate female patient ar willing use adequate method birth control duration study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>